<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jats-oasis2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10405751</article-id><article-id pub-id-type="pmid">37537881</article-id><article-id pub-id-type="doi">10.1080/14756366.2023.2242704</article-id><article-id pub-id-type="publisher-id">2242704</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Inhibition by components of <italic toggle="yes">Glycyrrhiza uralensis</italic> of 3CLpro and HCoV-OC43 proliferation</article-title><alt-title alt-title-type="left-running-head">J. H. Kim et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jang Hoon</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Yea-In</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Hur</surname><given-names>Mok</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Woo Tae</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Moon</surname><given-names>Youn-Ho</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Huh</surname><given-names>Yun-Chan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae IL</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Min Hye</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Jong Seong</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Chong Woon</given-names></name><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Junsoo</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AN0002" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Herbal Crop Research, National Institute of Horticultural &#x00026; Herbal Science, RDA</institution>, <state>Eumsung</state>, <country>Republic of Korea</country></aff><aff id="AF0002"><label>b</label><institution>Division of Biological Science and Technology, Yonsei University</institution>, <city>Wonju</city>, <country>Republic of Korea</country></aff><aff id="AF0003"><label>c</label><institution>College of Pharmacy, Chungnam National University</institution>, <city>Daejeon</city>, <country>Republic of Korea</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>*</label><p>These authors contributed equally to this work.</p></fn><fn id="AUFN2"><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/14756366.2023.2242704" ext-link-type="uri">https://doi.org/10.1080/14756366.2023.2242704</ext-link>.</p></fn><corresp id="AN0001">CONTACT Chong Woon Cho <email xlink:href="mailto:chongw113@naver.com">chongw113@naver.com</email>
<institution>College of Pharmacy, Chungnam National University</institution>, <city>Daejeon</city>, <country>Republic of Korea</country></corresp><corresp id="AN0002">Junsoo Park <email xlink:href="mailto:junsoo@yonsei.ac.kr">junsoo@yonsei.ac.kr</email>
<institution>Division of Biological Science and Technology, Yonsei University</institution>, <city>Wonju</city>, <country>Republic of Korea</country>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>3</day><month>8</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>8</month><year>2023</year></pub-date><volume>38</volume><issue>1</issue><elocation-id>2242704</elocation-id><pub-history><event event-type="received"><date><day>26</day><month>5</month><year>2023</year></date></event><event event-type="revised"><date><day>6</day><month>7</month><year>2023</year></date></event><event event-type="accepted"><date><day>26</day><month>7</month><year>2023</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>3</day><month>8</month><year>2023</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>3</day><month>8</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2023 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_38_2242704.pdf"/><abstract><title>Abstract</title><p>Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 3CLpro is a key enzyme in coronavirus proliferation and a treatment target for COVID-19. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in silico</italic>, compounds <bold>1</bold>&#x02013;<bold>3</bold> from <italic toggle="yes">Glycyrrhiza uralensis</italic> had inhibitory activity and binding affinity for 3CLpro. These compounds decreased HCoV-OC43 cytotoxicity in RD cells. Moreover, they inhibited viral growth by reducing the amounts of the necessary proteins (M, N, and RDRP). Therefore, compounds <bold>1</bold>&#x02013;<bold>3</bold> are inhibitors of 3CLpro and HCoV-OC43 proliferation.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>3CLpro</kwd><kwd>molecular simulation</kwd><kwd>HCoV-OC43</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>National Institute of Horticultural and Herbal Scienses, RDA</institution></institution-wrap>
</funding-source><award-id>PJ016777032023</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>National Institute of Horticultural and Herbal Scienses, RDA</institution></institution-wrap>
</funding-source></award-group><funding-statement>The research was supported by the basic research project (PJ016777032023) of the National Institute of Horticultural and Herbal Scienses, RDA.</funding-statement></funding-group></support-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="8"/><word-count count="4200"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><title>Introduction</title><p><italic toggle="yes">Glycyrrhiza uralensis</italic> (<italic toggle="yes">G. uralensis</italic>) belongs to the Leguminosae family, and its rhizomes are used as herbal medicines.<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref> The main components of this plant include glycyrrhizin (a triterpenoid saponin) and other polyphenols (liquritin, liquirtin apioside, isoliqurititin aposide, licoisoflavone A, and glycyrol).<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref> Glycyrrhizin, an FDA-approved natural sweetening compound, has antioxidant, antimicrobial, antifungal, and antiviral activities.<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref> Licochalcone A, isoliquiritigen, and liquiritigenin at 20&#x02009;&#x000b5;M increase UCP1 expression, thereby promoting 3T3-L1 adipocyte differentiation.<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref> Moreover, several polyphenols at 10&#x02009;&#x000b5;M increase Nrf2 expression; inhibit tyrosinase and PTP1B activity; and suppress NO production, NF-&#x003ba;B transcription, and the proliferation of HepG2, SW480, A549, and MCF7 cancer cells.<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref></p><p>Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref> COVID-19 is characterised by mild cold symptoms (fever, cough, tiredness, and loss of taste or smell; less commonly sore throat, headache, and diarrhea), and can be fatal, particularly in older people or those with underlying diseases.<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref> As of 10 March 2023, there had been a total of 759&#x02009;408&#x02009;703 COVID-19 cases and 6,866,434 deaths globally.<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref></p><p>SARS-CoV-2, of the <italic toggle="yes">Coronaviridae</italic>, is a positive-sense single-stranded RNA virus with a genome of &#x0223c;30,000 nucleotides and &#x0223c; 89.1% similarity to SARS-CoV.<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref> After entering the cell, the virus releases RNA, which is then translated into two polyproteins (pp1a and pp1ab).<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref> These have two cysteine proteases, the papain-like protease (PL<sup>pro</sup>) and the chymotrypsin-like protease (3CL<sup>pro</sup>).<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref> Especially, the latter is one of the most representative target enzymes for the development of SARS-CoV-2 inhibitors.<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref> Polyproteins are cleaved into non-structure proteins by 3CLpro, which are key factors in virus propagation.<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref> Thus, 3CLpro is a target for the development of therapeutics.<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref></p><p>We aimed to discover 3CLpro and HCoV-OC43 inhibitors from rhizomes of <italic toggle="yes">G. uralensis</italic>. Compounds <bold>1</bold>&#x02013;<bold>3</bold> inhibited 3CLpro <italic toggle="yes">in&#x000a0;vitro</italic> and <italic toggle="yes">in silico</italic> and affected HCoV-OC43 proliferation. Therefore, these compounds have potential as inhibitors of 3CLpro and HCoV-OC43.</p></sec><sec sec-type="materials" disp-level="1" id="S0002"><title>Materials and methods</title><sec disp-level="2" id="S0002-S2001"><title>General experimental procedures</title><p>NMR was conducted using a Bruker DRX-400 spectrometer (Bruker, Germany), with a chemical shift referenced to residual solvent signals and using MeOH-<italic toggle="yes">d</italic><sub>4</sub> as the solvent. Thin-layer chromatography (TLC) was performed on silica-gel 60 F254 and RP-18 F254S plates (0.25&#x02009;mm layer thickness; Merck, Darmstadt, Germany).<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref> Purified compounds were visualised on two TLC plates at a wavelength of 254&#x02009;nm. Silica gel (60&#x02009;A, 70&#x02013;230 or 230&#x02013;400 mesh ASTM; Merck) and reversed-phase silica gel (ODS-A 12&#x02009;nm S-150, S-75&#x02009;&#x000b5;m; YMC Co., Kyoto, Japan) were used for open-column chromatography. SARS-CoV-2 3CLpro was purchased from Sigma Aldrich (St. Louis, MO, USA). DABCY-LKTSAVLQSGFRKME-EDANS was synthesised by Anygen (Gwangju, Republic of Korea [ROK]).<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref></p></sec><sec disp-level="2" id="S0002-S2002"><title>Plant material</title><p>Rhizomes of <italic toggle="yes">G. uralensis</italic> were harvested from a farm in Eumsung, Chungcheongbuk-do, ROK in October 2015 and identified by Dr. Jeonghoon Lee. A voucher specimen (GUR151000_1) was deposited at the herbarium of the Department of Herbal Crop Research, National Institute of Horticultural and Herbal Science, ROK.</p></sec><sec disp-level="2" id="S0002-S2003"><title>Extraction and isolation</title><p>Rhizomes of <italic toggle="yes">G. uralensis</italic> (5&#x02009;kg) were extracted thrice with 95% ethanol for 2&#x02009;weeks. The solution was evaporated under reduced pressure to give an ethanol extract (&#x0223c; 240&#x02009;g). The concentrated extract was suspended in distilled water and divided into chloroform (&#x0223c; 80&#x02009;g) and ethyl acetate (&#x0223c; 85&#x02009;g) fractions. The chloroform fraction was subjected to silica gel column chromatography using a gradient solvent system of chloroform and methanol (10:0 to 0:10) to yield four fractions (1&#x02013;4). Fraction 1 was chromatographed on a C-18 column with a solvent system of water and methanol (60:40 to 20:80) to produce compound <bold>1</bold> (&#x0223c;5&#x02009;mg). Fraction 2 was chromatographed on a silica gel column with a solvent system of chloroform and methanol (9:1 to 1:9) to yield three fractions (21&#x02013;23). Compounds <bold>2</bold> (&#x0223c; 50&#x02009;mg) and <bold>3</bold> (&#x0223c;20&#x02009;mg) were purified from fraction 22 by C-18 column chromatography with a solvent system of water and methanol (60:40 to 20:80).</p></sec><sec disp-level="2" id="S0002-S2004"><title>3CLpro inhibition assay</title><p>This assay was performed as described previously with modification.<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref> 3CLpro (140&#x02009;&#x000b5;L; 13.3&#x02009;&#x000b5;g/mL) in 20&#x02009;mM Tris-HCl buffer (pH 7.5) was mixed with 10&#x02009;&#x000b5;L of MeOH or compound in MeOH (1.56&#x02013;100&#x02009;&#x000b5;M) in a 96-well plate, and 50&#x02009;&#x000b5;L of 100&#x02009;&#x000b5;M substrate was added. After starting the reaction at 37&#x02009;&#x000b0;C, the product was quantified using a fluorescence spectrophotometer at emission and excitations wavelengths of 530 and 340&#x02009;nm, respectively, with a gain of 85 for 30&#x02009;min.<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref></p></sec><sec disp-level="2" id="S0002-S2005"><title>Molecular docking</title><p>This study was performed as described by Kim <italic toggle="yes">et&#x000a0;al.</italic><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref> The three-dimensional (3D) structures of the compounds were constructed and minimised using Chem3D Pro (CambridgeSoft, Cambridge, MA, USA). The 3D structure of SARS CoV-2 3CLpro coded in 7END was downloaded from the RCSB Protein Data Bank. Water and ligand (J7R) were excluded from the 3D structure. Hydrogen was added to the protein using AutoDockTools (Scripps Research, La Jolla, CA, USA); the Gasteiger charge model was then applied.<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref> Flexible ligand docking was achieved using a torsion tree, with the detection of the torsion root and rotatable bonds. The grid box was set to a size of 60&#x02009;&#x000d7;&#x02009;60&#x02009;&#x000d7;&#x02009;60 at 0.375&#x02009;&#x000c5; for docking the ligand into the active site. Molecular docking was achieved via a Lamarckian genetic algorithm with the maximum number of evaluations. The resulting values were calculated and represented using Chimaera 1.14 (San Francisco, CA, USA), and LIGPLOT (European Bioinformatics Institute, Hinxton, UK).<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref></p></sec><sec disp-level="2" id="S0002-S2006"><title>Molecular dynamics</title><p>Molecular dynamics analysis was performed as described previously.<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref> The Gromacs 4.6.5 package was used to simulate the complex of 3CLpro with polyphenols. The complex was charged by a Gromos96 54a6 force field. Ligand topology was generated by The GlycoBioChem PRODRG Server. The charged complex was dissolved in water in a cubic box using the simple point charge water model and ionised with sodium. mdp files were generated following the instructions for GROMACS.<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref> The mdp files were minimised to a maximal force of 10&#x02009;kJ/mol using the steepest-descent method. The product was further equilibrated by 300&#x02009;K NVT in 1&#x02009;bar NPT for 100&#x02009;ps. Finally, a molecular dynamics simulation was conducted for 30&#x02009;ns. The results were analysed using g_utility. The data were visualised using SigmaPlot (San Jose, CA, USA) and Chimaera (San Francisco, CA, USA).<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref></p></sec><sec disp-level="2" id="S0002-S2007"><title>Cell culture and plaque formation assay</title><p>RD cells were maintained in MEM (Welgene, Seoul, ROK) containing 10% foetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin-streptomycin solution (Welgene).<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref> RD cells were infected with HCoV-OC43 at the indicated dilutions of medium from virus-infected cells, and the infected cells were maintained in MEM containing 2% FBS and 1% penicillin-streptomycin. Cell viability was measured by 3&#x02013;(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. HCoV-OC43 virus was obtained from the ATCC (Rockville, MD, USA) and RD cells from the Korean Cell Line Bank (KCLB, Seoul, ROK). MTT was purchased from USB Corporation (Cleveland, OH, USA). Plaque formation assay was performed to enumerate the virus.<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref> RD cells were seeded in a 12-well plate 1&#x02009;day prior to infection. Medium-containing coronavirus was diluted 10-fold in MEM (Welgene) with 2% FBS (Thermo Fisher Scientific) and 1% penicillin-streptomycin (Welgene). A diluted medium was added to RD cells, which were subsequently incubated for 1&#x02009;h at 33&#x02009;&#x000b0;C in 5% CO<sub>2</sub>. An overlay medium containing 0.6% agarose was added to each well and incubated for 3&#x02009;days. Next, the cells were fixed in 10% formaldehyde and stained with 1% crystal violet to visualise plaques.<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref></p></sec><sec disp-level="2" id="S0002-S2008"><title>Western blot and quantitative RT-PCR</title><p>For western blotting, cells and medium were added to the buffer (150&#x02009;mM NaCl, 50&#x02009;mM HEPES [pH 7.5], and 1% NP40) containing a protease inhibitor cocktail (Roche, Basel, Switzerland). Equal amounts of samples were resolved by SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). Viral proteins were detected using a primary anti-HCoV-OC43 antibody (1:5000 dilution) and an ECL system (Dogen, Seoul, ROK). Images were acquired using a Chemidoc (Bio-Rad).<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref></p><p>For quantitative RT-PCR, cells and media were collected and RNA was extracted using TRIzol (Thermo Fisher Scientific) in accordance with the manufacturer&#x02019;s instructions. RT-PCR was performed using the StepOnePlus&#x02122; Real-Time PCR System (Thermo Fisher Scientific). The HCoV-OC43 RdRp gene was amplified using the forward primer 5&#x02032;-GAGTGTAGATGCCCGTCTCG-3&#x02032; and reverse primer 5&#x02032;-TGTGGCACACGACTACCTTC-3&#x02032;. The HCoV-OC43 M gene was amplified using the forward primer 5&#x02032;-ACGGTCACAATAATACGCGGT-3&#x02032; and reverse primer 5&#x02032;-GGGTTGATGGCAGTCG GTAA-3&#x02032;. The HCoV-OC43 N gene was amplified using the forward primer 5&#x02032;-AGGATGCCACCAAACCTCAG-3&#x02032; and reverse primer 5&#x02032;-TGGGGAACTGTGGGTCACT A-3&#x02032;.<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref></p></sec><sec disp-level="2" id="S0002-S2009"><title>Statistical analysis</title><p>All measurements were performed in triplicate across three independent experiments, and the results are shown as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). The results of MTT were evaluated by a 2-tailed Student&#x02019;s <italic toggle="yes">t</italic>-test using Excel software (Microsoft, Redmond, WA, USA). The results were analysed using Sigma Plot (Systat Software Inc., San Jose, CS, USA).</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><title>Results</title><sec disp-level="2" id="S0003-S2001"><title>Isolation and identification of compounds 1&#x02013;3 from G. uralensis</title><p>Ethanol extract from rhizomes of <italic toggle="yes">G. uralensis</italic> was divided into chloroform, ethyl acetate, and water fractions. The chloroform fraction was purified by open-column chromatography to yield compounds <bold>1</bold>&#x02013;<bold>3</bold>. Their chemical structures were elucidated by <sup>1</sup>H- and <sup>13</sup>C-nuclear magnetic resonance and compared with prior reports. The compounds were identified as <italic toggle="yes">2&#x02032;</italic>-methoxyisoliquiritigenin (<bold>1</bold>)<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, glycycoumarin (<bold>2</bold>)<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>, and isoangustone A (<bold>3</bold>)<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref> (<xref rid="F0001" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F0001"><label>Figure 1.</label><caption><p>The structure of isolated compounds from <italic toggle="yes">G. uralensis.</italic></p></caption><graphic xlink:href="IENZ_A_2242704_F0001_B" content-type="black-white" position="float"/></fig></sec><sec disp-level="2" id="S0003-S2002"><title>The inhibitory activity of compounds 1&#x02013;3 on SARS-CoV-2 3CLpro</title><p>The inhibitory activities of compounds <bold>1</bold>&#x02013;<bold>3</bold> towards SARS-CoV-2 3CLpro were evaluated. The amount (increased fluorescence intensity) of the substrate (DABCYL-KTSAVLQVSGFRKME-EDANS) hydrolysed by 3CLpro was determined. The three compounds inhibited enzyme activity in a dose-dependent manner (IC<sub>50</sub> values 8.2&#x02009;&#x000b1;&#x02009;1.5, 0.6&#x02009;&#x000b1;&#x02009;0.2, and 5.2&#x02009;&#x000b1;&#x02009;0.9&#x02009;&#x000b5;M, respectively; <xref rid="F0002" ref-type="fig">Figure 2(A)</xref> and <xref rid="t0001" ref-type="table">Table 1</xref>).</p><fig position="float" id="F0002"><label>Figure 2.</label><caption><p>The inhibitory activity of compounds on SARS-CoV-2 3CLpro (A). The best pose (B) and docking results (C&#x02013;E) between inhibitors (<bold>1</bold>: red, <bold>2</bold>: yellow, <bold>3</bold>: green) and 3CLpro (ID: 7END).</p></caption><graphic xlink:href="IENZ_A_2242704_F0002_C" content-type="color" position="float"/></fig><table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>The inhibitory activity and docking results of inhibitors towards SARS-CoV-2 3CLpro.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">&#x000a0;</th><th colspan="2" align="center">Inhibitory activity<hr/></th><th align="center">Autodock score (kcal/mol)</th></tr><tr><th align="center">at 50 &#x000b5;M(%)</th><th align="center">IC<sub>50</sub>(&#x000b5;M)</th><th align="center">Hydrogen bonds</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="char" char=".">1</td><td rowspan="2" align="char" char=".">73.2</td><td rowspan="2" align="char" char=".">8.2&#x02009;&#x000b1;&#x02009;1.5</td><td align="char" char=".">&#x02212;7.31;</td></tr><tr><td align="left">His163(3.16), Ser144(2.92), Arg188(2.98), Thr190(3.13), Gln192(3.09)</td></tr><tr><td rowspan="2" align="char" char=".">2</td><td rowspan="2" align="char" char=".">&#x0003e;100</td><td rowspan="2" align="char" char=".">0.6&#x02009;&#x000b1;&#x02009;0.2</td><td align="char" char=".">&#x02212;9.62;</td></tr><tr><td align="left">Cys145(3.24), Glu166(2.98), Thr190(3.28), Gln192(2.56, 2.93)</td></tr><tr><td rowspan="2" align="char" char=".">3</td><td rowspan="2" align="char" char=".">78.7</td><td rowspan="2" align="char" char=".">5.2&#x02009;&#x000b1;&#x02009;0.9</td><td align="char" char=".">&#x02212;9.83;</td></tr><tr><td align="left">Cys145(2.94),Glu166(3.07, 3.21), Arg188(3.18), Thr190(2.78, 2.62, 2.47), Gln192(2.69)</td></tr></tbody></table></table-wrap></sec><sec disp-level="2" id="S0003-S2003"><title>The predicted binding site of inhibitors with 3CLpro</title><p>To assess the predicted interactions of the compounds with SARS-CoV-2 3CLpro, a molecular docking analysis was performed. Flexible ligands were stably docked in similar positions of the active site with Autodock scores of &#x02212;7.31, &#x02212;9.62, and &#x02212;9.83&#x02009;kcal/mol, respectively (<xref rid="F0002" ref-type="fig">Figure 2(B)</xref> and <xref rid="t0001" ref-type="table">Table 1</xref>). Compound <bold>1</bold> had five hydrogen bonds with His162 (3.16), Ser144 (2.92&#x02009;&#x000c5;), Arg188 (2.98&#x02009;&#x000c5;), Thr190 (3.13&#x02009;&#x000c5;), and Gln192 (3.09&#x02009;&#x000c5;). Compound <bold>2</bold> had five hydrogen bonds with Cys145 (3.24&#x02009;&#x000c5;), Glu166 (2.98), Thr190 (3.28&#x02009;&#x000c5;), and Gln192 (2.56&#x02009;&#x000c5;, 2.93&#x02009;&#x000c5;). Compound <bold>3</bold> formed eight hydrogen bonds with five amino acids&#x02013;Cys145 (2.94&#x02009;&#x000c5;), Glu166 (3.07&#x02009;&#x000c5;, 3.21&#x02009;&#x000c5;), Arg188 (3.18&#x02009;&#x000c5;), Thr190 (2.47&#x02009;&#x000c5;, 2.62&#x02009;&#x000c5;, 2.78&#x02009;&#x000c5;), and Gln192 (2.69&#x02009;&#x000c5;).</p></sec><sec disp-level="2" id="S0003-S2004"><title>Molecular dynamics study of the inhibitors with SARS-CoV-2 3CLpro</title><p>To evaluate inhibitor (I)&#x02013;enzyme (E) interactions, I&#x02009;+&#x02009;E complexes with ions and water were subjected to molecular dynamics analysis. Compounds <bold>1</bold>&#x02013;<bold>3</bold> moved to the active site according to the fluid movement of SARS-CoV-2 3CLpro (<xref rid="F0003" ref-type="fig">Figure 3(A&#x02013;C)</xref>). Compounds <bold>1</bold>, <bold>2</bold>, and <bold>3</bold> showed protein-based root-mean-square deviation (RMSD) values of 0.5, 0.4, and 0.3&#x02009;nm, respectively (<xref rid="F0003" ref-type="fig">Figure 3(D)</xref>), and their root-mean-square deviation (RMSF) values had similar shapes (<xref rid="F0003" ref-type="fig">Figure 3(E)</xref>). The compounds consisted of 1&#x02013;2 (<bold>1</bold>), 1&#x02013;4 (<bold>2</bold>), and 1&#x02013;2 (<bold>3</bold>) hydrogen bonds (<xref rid="F0003" ref-type="fig">Figure 3(F&#x02013;H)</xref>). Compounds <bold>1</bold> and <bold>2</bold> maintained a &#x0223c; 3.5&#x02009;&#x000c5; distance from Glu166, Thr190, and Gln192. Inhibitor <bold>3</bold> showed movement at a &#x0223c; 4&#x02009;&#x000c5; distance with two Glu166 and Gln192 (<xref rid="F0003" ref-type="fig">Figure 3(I&#x02013;L)</xref>).</p><fig position="float" id="F0003"><label>Figure 3.</label><caption><p>The superposition of inhibitors <bold>1</bold>&#x02013;<bold>3</bold> with sEH for the 30&#x02009;ns (red: 0&#x02009;ns, orange: 3&#x02009;ns, yellow: 6&#x02009;ns, green: 9&#x02009;ns, cyan: 12&#x02009;ns, blue: 15&#x02009;ns, conflower blue: 18&#x02009;ns, purple: 21&#x02009;ns, hot pink: 24&#x02009;ns, magenta: 27&#x02009;ns, black: 30&#x02009;ns) (A-C). The RMSD (D), RMSF (E), and hydrogen bonds (F&#x02013;H) of the simulation. The distance of key residues (I) with inhibitors <bold>10</bold> with sEH(J&#x02013;L).</p></caption><graphic xlink:href="IENZ_A_2242704_F0003_C" content-type="color" position="float"/></fig></sec><sec disp-level="2" id="S0003-S2005"><title>The decreases of coronavirus-induced cytotoxicity by compounds 1&#x02013;3</title><p>Because compounds <bold>1</bold>&#x02013;<bold>3</bold> inhibited SARS-CoV-2 3CLpro, we examined their effects on coronavirus replication and their cytotoxicity. Compounds <bold>1</bold>&#x02013;<bold>3</bold> at 20&#x02009;&#x000b5;M decreased cell viability, but at 1.25&#x02013;10&#x02009;&#x000b5;M did not show significant cytotoxicity (<xref rid="F0004" ref-type="fig">Figure 4(A&#x02013;C)</xref>). Therefore, we used compounds <bold>1</bold>&#x02013;<bold>3</bold> at &#x02264;10&#x02009;&#x000b5;M. HCoV-OC43-infected cells showed a viability rate of &#x0223c;60% that of uninfected cells. Compounds <bold>1</bold>&#x02013;<bold>3</bold> reduced coronavirus-induced cytotoxicity in a dose-dependent manner (<xref rid="F0004" ref-type="fig">Figure 4(D&#x02013;F)</xref>). Compound <bold>2</bold> at 5&#x02009;&#x000b5;M resulted in a &#x0223c; 90% viability rate but was cytotoxic at 10&#x02009;&#x000b5;M. Therefore, compounds <bold>1</bold>&#x02013;<bold>3</bold> suppressed coronavirus-induced cytotoxicity.</p><fig position="float" id="F0004"><label>Figure 4.</label><caption><p>Compounds <bold>1</bold>&#x02013;<bold>3</bold> treatment decreased HCoV-OC43-induced cytotoxicity. The cytotoxicity of compounds <bold>1</bold>&#x02013;<bold>3</bold> was evaluated by MTT assay (A&#x02013;C). RD cells were incubated with the indicated concentration of compounds <bold>1</bold>&#x02013;<bold>3</bold> for 24&#x02009;h. Compounds <bold>1</bold>&#x02013;<bold>3</bold> treatment reduces the cytotoxicity of HCoV-OC43 infections (D&#x02013;F). RD cells were infected with mock or HCoV-OC43 and cells were incubated with the indicated concentration of compound. Cell viability was evaluated with MTT assay.</p></caption><graphic xlink:href="IENZ_A_2242704_F0004_C" content-type="color" position="float"/></fig></sec><sec disp-level="2" id="S0003-S2006"><title>The inhibition and reduced plaque formation of coronavirus replication by compounds 1&#x02013;3</title><p>The 3D-structure of 3CLpro of HCOV-OC43 was derived through molecular homology technology. As a result of docking the compounds <bold>1</bold>&#x02013;<bold>3</bold> to the predictive model, a value similar to those of SARS-CoV-2 3CLpro was confirmed (<ext-link xlink:href="https://doi.org/10.1080/14756366.2023.2242704" ext-link-type="uri">Figure S4, S5</ext-link>, <ext-link xlink:href="https://doi.org/10.1080/14756366.2023.2242704" ext-link-type="uri">Table S1</ext-link>).</p><fig position="float" id="F0005"><label>Figure 5.</label><caption><p>Compounds <bold>1</bold>&#x02013;<bold>3</bold> inhibited the replication of HCoV-OC43 coronavirus. (A) Compounds <bold>1</bold>&#x02013;<bold>3</bold> treatment decreased the expression of HCoV-OC43 protein in cells and media. RD cells were incubated with compounds <bold>1</bold>&#x02013;<bold>3</bold> and infected with HCoV-OC43 (1 0 <sup>&#x02212;3</sup> dilution of conditioned media). Three days after infection, an equal amount of cell lysates (upper panel) and conditioned media (lower panel) were probed with anti-HCoV-OC43 antibody. (B) Compounds <bold>1</bold>&#x02013;<bold>3</bold> treatment decreased the RNA level of HCoV-OC43 in media. RD cells were infected HCoV-OC43, and RNA was purified from the infected cell and media. The RNA level of RdRp gene, M gene and N gene was evaluated by quantitative RT-PCR.</p></caption><graphic xlink:href="IENZ_A_2242704_F0005_C" content-type="color" position="float"/></fig><p>Because compounds <bold>1</bold>&#x02013;<bold>3</bold> suppressed coronavirus-induced cytotoxicity, we hypothesised that they would inhibit coronavirus replication. Western blotting using an anti-OC43 antibody showed that compounds <bold>1</bold>&#x02013;<bold>3</bold> decreased coronavirus protein levels in a dose-dependent manner (<xref rid="F0005" ref-type="fig">Figure 5(A)</xref>). Interestingly, compound <bold>1</bold> decreased the viral protein level in the conditioned medium but did not affect that in cell lysate, suggesting interference with the viral release (<xref rid="F0005" ref-type="fig">Figure 5(A)</xref>). Quantitative RT-PCR showed that the mRNA levels of the M, N, and RDRP proteins of HCoV-OC43 were decreased by compounds <bold>1</bold>&#x02013;<bold>3</bold> (<xref rid="F0005" ref-type="fig">Figure 5(B)</xref>). Therefore, compounds <bold>1</bold>&#x02013;<bold>3</bold> inhibited coronavirus replication. Because they inhibited coronavirus replication, we examined their effects on plaque formation. Compounds <bold>1</bold>&#x02013;<bold>3</bold> decreased the number of plaques, indicating inhibition of coronavirus replication (<xref rid="F0006" ref-type="fig">Figure 6</xref>).</p><fig position="float" id="F0006"><label>Figure 6.</label><caption><p>Compounds <bold>1</bold>&#x02013;<bold>3</bold> reduced the number of plaque formation. RD cells were infected with HCoV-OC43 and cells were incubated with compounds <bold>1</bold>&#x02013;<bold>3</bold>. To visualise the plaque formation, the infected cells were stained with crystal violets.</p></caption><graphic xlink:href="IENZ_A_2242704_F0006_C" content-type="color" position="float"/></fig></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><title>Discussion</title><p>Four coronaviruses (229E, OC43, NL63, HKU1) are responsible for 10&#x02013;30% of common cold cases, SARS-CoV in 2002, MERS-CoV in 2013, and SARS-CoV-2 in 2019.<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref> Although the COVID-19 outbreak in 2019 had a &#x0223c; 0.9% fatality rate, it has killed millions of people because of rapid SARS-CoV-2 transmission.<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref> Despite the development of vaccines and drugs, these viruses continue to threaten public health.<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref> For this reason, phytochemists have focused on developing antiviral drugs from natural products.<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref> Glycyrrhizin and glycyrrhetinic acid of <italic toggle="yes">Glycyrrhiza glabra</italic> suppress the proliferation and infection of RNA and DNA viruses.<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref> We focused on polyphenols rather than triterpenoids in rhizomes of <italic toggle="yes">G. uralensis</italic>. Compounds <bold>1</bold>&#x02013;<bold>3</bold> inhibited substrate cleavage by 3CLpro with IC<sub>50</sub> values of 8.2&#x02009;&#x000b1;&#x02009;1.5, 0.6&#x02009;&#x000b1;&#x02009;1.2, and 5.2&#x02009;&#x000b1;&#x02009;0.9&#x02009;&#x000b5;M, respectively. Also, the three compounds showed similar binding forces at the active site. Compounds <bold>1</bold>&#x02013;<bold>3</bold> had similar numbers of hydroxyl, ketone, and methyl groups, which can participate in hydrogen bonding. Molecular dynamics can provide insight into flexible drug-target interactions.<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref> A force field based on Newton&#x02019;s physics is responsible for a role calculating the atom forces and the energy of the complex.<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref> The results showed that three (Glu166, Thr190, and Gln192) or two (Glu166 and Gln192) residues maintain a continuous distance during the binding of the inhibitor with 3CLpro in a fluid state. Glu166 participated in hydrogen bonding to the three compounds. The inhibition of 3CLpro catalysis plays an important role in inhibitiing coronavirus replication.<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>&#x02013;</sup><xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>&#x000a0;. It was confirmed through homology modelling that SARS-CoV-2 and HCoV-OC43, which are beta coronaviruses, have similar 3CLpro.<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref> We evaluated the effects of compounds <bold>1</bold>&#x02013;<bold>3</bold> on viral cytotoxicity and replication in HCoV-OC43-infected cells. RD cells were protected from infected HCoV-OC43 when treated with compounds <bold>1</bold> and <bold>3</bold> at 10&#x02009;&#x000b5;M, and <bold>2</bold> at 5&#x02009;&#x000b5;M. Compounds <bold>2</bold> and <bold>3</bold> reduced the HCoV-OC43 protein level in cells and media, and compound <bold>1</bold> only in the medium. Therefore, compound <bold>1</bold> is more effective in releasing viruses than inhibiting viral replication in infected cells. Moreover, the three compounds at 5 and 10&#x02009;&#x000b5;M not only reduced the levels of M, N, and RDRP genes that were relicated by proteins cleaved from polyprotein by 3CLpro&#x000a0; but also inhibited HCoV-OC43 proliferation, an effect confirmed by the results of plaque assays.</p><p>Methoxyisoliquiritigenin (<bold>1</bold>), glycycoumarin (<bold>2</bold>), and isoangustone A (<bold>3</bold>) from rhizomes of <italic toggle="yes">G. uralensis</italic> inhibited 3CLpro with IC<sub>50</sub> values of 8.2&#x02009;&#x000b1;&#x02009;1.5, 0.6&#x02009;&#x000b1;&#x02009;0.2, and 5.2&#x02009;&#x000b1;&#x02009;0.9&#x02009;&#x000b5;M, respectively. <italic toggle="yes">In silico</italic>, compounds <bold>1</bold>&#x02013;<bold>3</bold> stably bonded with Glu166, Thr190, and Gln192 and inhibited the production of M, N, and RDRP proteins during HCoV-OC43 proliferation. Finally, we confirmed the antiviral effects of these compounds by measuring viral protein expression, RNA expression, and plaque formation with the coronavirus model system (<xref rid="F0005" ref-type="fig">Figures 5</xref> and <xref rid="F0006" ref-type="fig">6</xref>). In conclusion, compounds <bold>1</bold>&#x02013;<bold>3</bold> have potential as candidates or lead compounds for the development of therapies for coronavirus infection.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM8842" position="float" content-type="local-data"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_2242704_SM8842.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec sec-type="COI-statement" disp-level="1" id="S0005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>X.</given-names></string-name></person-group>
<article-title>Natural polysaccharides from <italic toggle="yes">Glycyrrhiza uralensis</italic> residues with typical glucan structure showing inhibition on &#x003b1;-glucosidase activities</article-title>. <source>Int J Biol Macromol</source>. <year>2023</year>; <volume>224</volume>:<fpage>776</fpage>&#x02013;<lpage>785</lpage>.<pub-id pub-id-type="pmid">36280177</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Dinteren</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Meijerink</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Witkamp</surname>
<given-names>R</given-names></string-name>, <string-name><surname>van Ieperen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Vincken</surname>
<given-names>J-P</given-names></string-name>, <string-name><surname>Araya-Cloutier</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Valorisation of liquorice (<italic toggle="yes">Glycyrrhiza</italic>) roots: antimicrobial activity and cytotoxicity of prenylated (iso)flavonoids and chalcones from liquorice spent (<italic toggle="yes">G. glabra</italic>, <italic toggle="yes">G. inflata</italic>, and <italic toggle="yes">G. uralensis</italic>)</article-title>. <source>Food Funct</source>. <year>2022</year>;<volume>13</volume>(<issue>23</issue>):<fpage>12105</fpage>&#x02013;<lpage>12120</lpage>.<pub-id pub-id-type="pmid">36377761</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Ji</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>S-w</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>X-h</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>H-w</given-names></string-name>, <string-name><surname>Duan</surname>
<given-names>Y-k</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>L-r</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>D-a</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Identification of key licorice constituents which interact with cytochrome P450: Evaluation by LC/MS/MS cocktail assay and metabolic profiling</article-title>. <source>Aaps J</source>. <year>2014</year>;<volume>16</volume>(<issue>1</issue>):<fpage>101</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">24254844</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muthu</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Sharma</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Qureshi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Parvez</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ahmad</surname>
<given-names>B.</given-names></string-name></person-group>
<article-title>Mechanistic insights into monomer level prevention of amyloid aggregation of lysozyme by glycyrrhizic acid</article-title>. <source>Int J Biol Macromol</source>. <year>2023</year>;<volume>227</volume>:<fpage>884</fpage>&#x02013;<lpage>895</lpage>.<pub-id pub-id-type="pmid">36549619</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langer</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mlynarczyk</surname>
<given-names>DT</given-names></string-name>, <string-name><surname>Dlugaszewska</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tykarska</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Potential of glycyrrhizic and glycyrrhetinic acids against influenza type A and B viruses: a perspective to develop new anti-influenza compounds and drug delivery systems</article-title>. <source>Eur J Med Chem</source>. <year>2023</year>;<volume>246</volume>:<fpage>114934</fpage>.<pub-id pub-id-type="pmid">36455358</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>HE</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>S-H</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>J-H</given-names></string-name>, <string-name><surname>An</surname>
<given-names>T-J</given-names></string-name>, <string-name><surname>Jang</surname>
<given-names>J-K</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JY.</given-names></string-name></person-group>
<article-title>Anti-obesity potential of <italic toggle="yes">Glycyrrhiza uralensis</italic> and licochalcone A through induction of adipocyte browning</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2018</year>;<volume>503</volume>(<issue>3</issue>):<fpage>2117</fpage>&#x02013;<lpage>2123</lpage>.<pub-id pub-id-type="pmid">30093114</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ji</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Kuang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Qiao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Glycybridins A&#x02009;&#x02212;&#x02009;K, bioactive phenolic compounds from <italic toggle="yes">Glycyrrhiza glabra</italic></article-title>. <source>J Nat Prod</source>. <year>2017</year>;<volume>80</volume>(<issue>2</issue>):<fpage>334</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">28140583</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keretsu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bhujbal</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>SJ.</given-names></string-name></person-group>
<article-title>Rational approach toward COVID&#x02011;19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>17716</fpage>.<pub-id pub-id-type="pmid">33077821</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>, Coronavirus disease (COVID-19). <ext-link xlink:href="https://www.who.int/health%20-%20topics/coronavirus#tab=tab_1" ext-link-type="uri">https://www.who.int/health - topics/coronavirus#tab=tab_1</ext-link>. (acessed data: 10 March <year>2023</year>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberle</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Olivier</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Amaral</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Gering</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Willbold</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Arni</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Coronado</surname>
<given-names>MA.</given-names></string-name></person-group>
<article-title>The repurposed drugs suramin and quinacrine cooperatively inhibit SARS-CoV-2 3CL<sup>pro</sup>
<italic toggle="yes">in&#x000a0;vitro</italic></article-title>. <source>Viruses</source>. <year>2021</year>;<volume>13</volume>:<fpage>873</fpage>.<pub-id pub-id-type="pmid">34068686</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Citarella</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scala</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Piperno</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Micale</surname>
<given-names>N.</given-names></string-name></person-group>
<article-title>SARS-CoV Mpro: a potential target for peptidominetics and small-molecule inhibitors</article-title>. <source>Biomolecules</source>. <year>2021</year>;<volume>11</volume>:<fpage>607</fpage>.<pub-id pub-id-type="pmid">33921886</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Sacco</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Meng</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Szeto</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, Telaprevir, and Boceprevir</article-title>. <source>ACS Pharmacol Transl Sci</source>. <year>2021</year>;<volume>4</volume>(<issue>4</issue>):<fpage>1408</fpage>&#x02013;<lpage>1421</lpage>.<pub-id pub-id-type="pmid">34414360</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Melo-Filho</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Bobrowski</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Martin</surname>
<given-names>H-J</given-names></string-name>, <string-name><surname>Sessions</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Popov</surname>
<given-names>KI</given-names></string-name>, <string-name><surname>Moorman</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Baric</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Muratov</surname>
<given-names>EN</given-names></string-name>, <string-name><surname>Tropsha</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Conserved coronavirus proteins as target of broad-spectrum antivirals</article-title>. <source>Antiviral Res</source>. <year>2022</year>;<volume>204</volume>:<fpage>105360</fpage>.<pub-id pub-id-type="pmid">35691424</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>V&#x02019;kovski</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kratzel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Steiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Stalder Thiel</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Coronavirus biology and replication: implications for SARS-CoV-2</article-title>. <source>Nat Rev</source>. <year>2021</year>;<volume>19</volume>:<fpage>155</fpage>&#x02013;<lpage>170</lpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nand</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maiti</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Joshi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Chandra</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pande</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kuniyal</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Ramakrishnan</surname>
<given-names>MA.</given-names></string-name></person-group>
<article-title>Virtual screening of anti&#x02011;HIV1 compounds against SARS&#x02011;CoV&#x02011;2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>20397</fpage>.<pub-id pub-id-type="pmid">33230180</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>
<given-names>Y-I</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Eupatin, a flavonoid, inhibits coronavirus 3CL protease and replication</article-title>. <source>Inter J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>9221</fpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>Y-I</given-names></string-name>, <string-name><surname>Hur</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>WT</given-names></string-name>, <string-name><surname>Moon</surname>
<given-names>Y-H</given-names></string-name>, <string-name><surname>Koo</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Her</surname>
<given-names>Y-C</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>The inhibitory activity of methoxyl flavonoids derived from <italic toggle="yes">Inula britannica</italic> flowers on SARS-CoV-2 3CLpro</article-title>. <source>Int J Biol Macromol</source>. <year>2022</year>;<volume>222</volume>(<issue>Pt B</issue>):<fpage>2098</fpage>&#x02013;<lpage>2104</lpage>.<pub-id pub-id-type="pmid">36208809</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>M-S</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>DH.</given-names></string-name></person-group>
<article-title>Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>1539</fpage>&#x02013;<lpage>1544</lpage>.<pub-id pub-id-type="pmid">32746637</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>SY.</given-names></string-name></person-group>
<article-title>Inhibition of soluble epoxide hydrolase by phytochemical constituents of the root bark of <italic toggle="yes">Ulmus davidiana</italic> var. japonica</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2021</year>;<volume>36</volume>(<issue>1</issue>):<fpage>1049</fpage>&#x02013;<lpage>1055</lpage>.<pub-id pub-id-type="pmid">34000951</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>Y-I</given-names></string-name>, <string-name><surname>Cha</surname>
<given-names>Y-E</given-names></string-name>, <string-name><surname>Yamamoto</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>EGCC, a green tea polyphenol, inhibits human coronavirus replication <italic toggle="yes">in&#x000a0;vitro</italic></article-title>. <source>Biochem Biophys Res Commun</source>. <year>2021</year>;<volume>547</volume>:<fpage>23</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">33588235</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryu</surname>
<given-names>YB</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>S-J</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Rho</surname>
<given-names>M-C</given-names></string-name>, <string-name><surname>Bae</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>WS.</given-names></string-name></person-group>
<article-title>Inhibition of neuraminidase activity by polyphenol compounds isolated from the roots of <italic toggle="yes">Glycyrrhiza uralensis</italic></article-title>. <source>Bioorg Med Chem Lett</source>. <year>2010</year>;<volume>20</volume>(<issue>3</issue>):<fpage>971</fpage>&#x02013;<lpage>974</lpage>.<pub-id pub-id-type="pmid">20064716</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gafner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bergeron</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Villinski</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Godejohann</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kessler</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cardellina</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Ferreira</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Feghali</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Grenier</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Isoflavonoids and coumarins from <italic toggle="yes">Glycyrrhiza uralensis</italic>: antibacterial activity against oral pathogens and conversion of isoflavans into isoflavan-quinones during purification</article-title>. <source>J Nat Prod</source>. <year>2011</year>;<volume>74</volume>(<issue>12</issue>):<fpage>2514</fpage>&#x02013;<lpage>2519</lpage>.<pub-id pub-id-type="pmid">22074222</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seon</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>J-K</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kwon</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>Yoon Park</surname>
<given-names>JH.</given-names></string-name></person-group>
<article-title>Isoangustone A present in hexane/ethanol extract of <italic toggle="yes">Glycyrrhiza uralensis</italic> induces apoptosis in DU145 human prostate cancer cells via the activation of DR4 and intrinsic apoptosis pathway</article-title>. <source>Mol Nutr Food Res</source>. <year>2010</year>;<volume>54</volume>(<issue>9</issue>):<fpage>1329</fpage>&#x02013;<lpage>1339</lpage>.<pub-id pub-id-type="pmid">20229524</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>Structural biology of SARS-CoV-2 and implications for therapeutic development</article-title>. <source>Nat Rev Microbiol</source>. <year>2021</year>;<volume>19</volume>(<issue>11</issue>):<fpage>685</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">34535791</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>R-M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>M-C</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>J-L</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>F-F</given-names></string-name>, <string-name><surname>Ko</surname>
<given-names>S-H</given-names></string-name>, <string-name><surname>Ke</surname>
<given-names>F-Y</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>S-C</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>K-H</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>JP-Y</given-names></string-name>, <string-name><surname>Chiang</surname>
<given-names>H-L</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>C-P</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>I-J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W-S</given-names></string-name>, <string-name><surname>Hsieh</surname>
<given-names>H-P</given-names></string-name>, <string-name><surname>Tao</surname>
<given-names>M-H</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>H-C.</given-names></string-name></person-group>
<article-title>A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies</article-title>. <source>J Biomed Sci</source>. <year>2022</year>;<volume>29</volume>(<issue>1</issue>):<fpage>68</fpage>.<pub-id pub-id-type="pmid">36096815</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bachar</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Mazumder</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bachar R. Aktar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Al Mahtab</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>A review of medicinal plants with antiviral activity available in Bangladesh and mechanistic insight into their bioactive metabolites on SARS-CoV-2, HIV and HBV</article-title>. <source>Frontiers Pharm</source>. <year>2021</year>;<volume>122</volume>:<fpage>732891</fpage>.</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diomede</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Beeg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gamba</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fumagalli</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Gobbi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Salmona</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Can antiviral activity of licorice help fight COVID-19 infection?</article-title>
<source>Biomolecules</source>. <year>2021</year>;<volume>11</volume>:<fpage>855</fpage>.<pub-id pub-id-type="pmid">34201172</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Vivo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Masett</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bottegoni</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cavalli</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Role of molecular dynamics and related methods in drug discovery</article-title>. <source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>(<issue>9</issue>):<fpage>4035</fpage>&#x02013;<lpage>4061</lpage>.<pub-id pub-id-type="pmid">26807648</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Milani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Donalisio</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bonotto</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Schneider</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Arduino</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Boni</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lembo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Marcello</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mastrangelo</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Combined <italic toggle="yes">in silico</italic> and <italic toggle="yes">in&#x000a0;vitro</italic> approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors</article-title>. <source>Antiviral Res</source>. <year>2021</year>;<volume>189</volume>:<fpage>105055</fpage>.<pub-id pub-id-type="pmid">33713730</pub-id></mixed-citation></ref></ref-list></back></article>